The global human milk oligosaccharide (HMO) market is estimated to reach USD 100.8 million in 2024. Over the forecast period, human milk oligosaccharide sales are poised to increase at a CAGR of 6.5%. The global industry is estimated to reach a value of USD 161.6 million by 2034.
| Attributes | Key Insights |
|---|---|
| Estimated Global Human Milk Oligosaccharide (HMO) Market Size (2024E) | USD 100.8 million |
| Projected Human Milk Oligosaccharide (HMO) Market Value (2034F) | USD 161.6 million |
| Value-based CAGR (2024 to 2034) | 6.5% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
During the historical period, the global sales of human milk oligosaccharide increased steadily, driven by increasing awareness of their health benefits, particularly in infant nutrition. This period observed research and development of alternative methods to extract HMOs from human breast milk, such as microbial fermentation and enzymatic synthesis. These dynamics made it feasible to produce HMOs at scale.
Growing interest in HMOs attracted many investments from established firms and start-ups offering infant nutrition solutions. Additionally, the rising partnerships between companies, research institutions, and universities are facilitating research and product development.
Increased awareness of breastfeeding and human milk components has boosted consumer interest in HMO-containing products. Education initiatives, marketing campaigns, and healthcare professional endorsements are promoting acceptance.
Sales of human milk oligosaccharides are forecasted to expand at a CAGR of 6.5% by 2034. The market is projected to increase in size, thanks to various factors like growing research studies to uncover new health benefits of HMOs.
Extending use of infant nutrition into areas like dietary supplements, and increasing preference given to natural and bioactive ingredients, are likely to drive product demand.
The growth is expected to be fueled by regulatory support and improvements in production technology during the forecast period. Hence, manufacturers are expected to increasingly invest in production capacity expansion, research & development, and marketing efforts. These strategies are likely to enable them to meet the growing demand and exploit the opportunities presented by the expanding HMO market under study.
Principal Consultant
| Market Statistics | Details |
|---|---|
| Jul to Dec (H2), 2022 (A) | 6.8% |
| Jan to Jun (H1), 2022 (A) | 6.2% |
| Jan to Jun (H1), 2023 Projected (P) | 7.3% |
| Jan to Jun (H1), 2023 Outlook (O) | 6.9% |
| Jan to Jun (H1), 2024 Projected (P) | 10.0% |
| Jul to Dec (H2), 2023 Outlook (O) | 9.1% |
| Jul to Dec (H2), 2023 Projected (P) | 8.8% |
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The table below shows the estimated growth rates of the leading countries. The United Kingdom, China, and Germany are set to record high CAGRs of 6.2%, 5.5%, and 5.9%, respectively, through 2034.
| Countries | CAGR |
|---|---|
| United States | 4.5% |
| United Kingdom | 6.2% |
| Germany | 5.9% |
| China | 5.5% |
| Japan | 4.8% |
The United States is expected to exhibit a CAGR of 4.5% through 2034. Key factors supporting the market growth are:
The United States has a developed infrastructure for research and development, resulting in innovation in infant nutrition, which is driving market growth. The baby formula market in the United States is on the rise due to increasing awareness about breastfeeding and early nutrition benefits. It is largely driven by parents demanding products that resemble human breast milk.
Many corporate houses and several academic institutions across the country are involved with HMO-related research and development projects. These projects concentrate on enhancing production techniques, investigating novel uses, and comprehending the health advantages of HMOs in newborn nutrition.
During the forecast period, China is expected to expand at a CAGR of 5.5%. HMO-infused premium baby nutrition products are expected to be driven by factors like rising disposable income and urbanization in China.
Increasing initiatives by the government of China to promote breastfeeding and regulate infant formula standards are encouraging the use of HMO in infant formula. Further, Chinese players are into fostering collaborations between academic institutions, research facilities, and industry players to increase their stake.
The demand for human milk oligosaccharides in Japan is anticipated to steadily increase at a CAGR of 4.8% during the forecast period. The rising incidences of digestive disorders and food sensitivities among infants are pushing the sales of HMOs in Japan.
Additionally, consumer knowledge of HMOs is increasing due to rising marketing campaigns, educational initiatives, and healthcare industry endorsements. This is boosting the product’s acceptance among parents and caregivers. This is projected to accelerate product sales in the nation.
The section below shows the fucosylated segment dominating by product type. The segment is predicted to reach USD 42.9 million in 2034. Based on end-use, the infant formula segment is anticipated to generate a dominant share through 2024. It is set to reach USD 99.2 million by 2024.
| Segment | Infant Formula (End-use) |
|---|---|
| Market Value (2024) | USD 99.2 million |
Infant formula mimics breast milk's composition to provide effective nutrients to non-breastfed infants. By virtue of their role in gut health, immune function, and development, HMOs found in breast milk are crucial to be included in infant formulations for similar benefits. The use of HMOs in infant formulations is increasing due to strict regulatory standards, making HMOs a popular choice for infant health supplements.
| Segment | Fucosylated (Product Type) |
|---|---|
| Market Value (2034) | USD 42.9 million |
Fucosylated HMOs, like 2'-fucosyllactose and 3-fucosyllactose, are gaining traction as they are crucial for infant gut health. These also help in promoting beneficial bacteria growth and inhibiting pathogen adhesion.
Since they are the closest to human breast milk in mimicking their health benefits, manufacturers take an interest in fucosylated HMOs. They are projected to contribute to the development of a healthy gut microbiome essential for immune function and nutrient absorption.
The human milk oligosaccharide (HMO) market remains extremely dynamic and highly competitive. In line with this, key companies in the industry participate in research & development, new formulation, and sustainable sourcing to further capture markets.
Key players are focusing on obtaining product certifications, following environmentally friendly practices, and meeting the increased demand for natural ingredients and sustainability.
For instance
The market is set to reach USD 100.8 million in 2024.
Demand for human milk oligosaccharide is slated to expand at a 6.5% CAGR by 2034.
The market is set to reach USD 161.6 million in 2034.
KYOWA HAKKO BIO CO. LTD., DSM, and Nestle Health Science are the key players.
Fucosylated segment is estimated to hold a significant market share in 2024.
Asia Pacific is expected to hold a market share of 39.2% by 2034.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Technology Roadmap
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition
3. Market Dynamics
3.1. Drivers
3.1.1. Supply Side Drivers
3.1.2. Demand Side drivers
3.1.3. Economic Side Drivers
3.2. Restraints
3.3. Opportunity
3.4. Market trends By Region
3.5. Forecast Factors - Relevance & Impact
3.6. Key Regulations and Policies
4. Value Chain Analysis
4.1. Operating Margins at Each Node of the Supply Chain
4.2. List of Active Market Participants
5. Global - Pricing Analysis
5.1. Price Point Assessment by Region
5.1.1. Manufacturer-Level Pricing
5.1.2. Distributor Level Pricing
5.2. Price Point Assessment By Product
5.3. Price Forecast till 2034
6. Global Market Size (in Value (US$ million) and Volume (MT) Analysis 2019 to 2023 and Forecast, 2024 to 2034
6.1. Historical Market Size (in Value (US$ million) and Volume (MT) Analysis, 2019 to 2023
6.2. Current and Future Market Size (in Value (US$ million) and Volume (MT) Analysis, 2024 to 2034
6.2.1. Y-o-Y Growth Trend Analysis
6.2.2. Absolute $ Opportunity Analysis
7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Product Type
7.1. Introduction / Key Findings
7.2. Historical Market Size (in Value (US$ million) and Volume (MT) Analysis By Product Type, 2019 to 2023
7.3. Current and Future Market Size (in Value (US$ million) and Volume (MT) Analysis and Forecast By Product Type, 2024 to 2034
7.3.1. Fucosylated
7.3.1.1. 2FL
7.3.1.2. 2FL DFL
7.3.1.3. 3FL
7.3.2. Silylated
7.3.2.1. 3SL
7.3.2.2. 6SL
7.3.3. Non-fucosylated Neutral
7.3.3.1. LNT
7.3.3.2. LNnT
7.3.3.3. LNFP
7.4. Market Attractiveness Analysis By Product Type
8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By End-use
8.1. Introduction / Key Findings
8.2. Historical Market Size (in Value (US$ million) and Volume (MT) Analysis By End-use, 2019 to 2023
8.3. Current and Future Market Size (in Value (US$ million) and Volume (MT) Analysis and Forecast By End-use, 2024 to 2034
8.3.1. Infant Formula
8.3.2. Dietary Supplements
8.4. Market Attractiveness Analysis By End-use
9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Region
9.1. Introduction
9.2. Historical Market Size (in Value (US$ million) and Volume (MT) Analysis By Region, 2019 to 2023
9.3. Current Market Size (in Value (US$ million) and Volume (MT) Analysis and Forecast By Region, 2024 to 2034
9.3.1. North America
9.3.2. Latin America
9.3.3. Europe
9.3.4. East Asia
9.3.5. South Asia
9.3.6. Oceania
9.3.7. Middle East and Africa
9.4. Market Attractiveness Analysis By Region
10. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034
10.1. Introduction
10.2. Historical Market Size (US$ million) and Volume Trend Analysis By Market Taxonomy, 2019 to 2023
10.3. Market Size (US$ million) and Volume Forecast By Market Taxonomy, 2024 to 2034
10.3.1. By Country
10.3.1.1. United States
10.3.1.2. Canada
10.3.2. By Product Type
10.3.3. By End-use
10.4. Market Attractiveness Analysis
10.4.1. By Country
10.4.2. By Product Type
10.4.3. By End-use
10.5. Key Takeaways
11. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034
11.1. Introduction
11.2. Historical Market Size (US$ million) and Volume Trend Analysis By Market Taxonomy, 2019 to 2023
11.3. Market Size (US$ million) and Volume Forecast By Market Taxonomy, 2024 to 2034
11.3.1. By Country
11.3.1.1. Brazil
11.3.1.2. Mexico
11.3.1.3. Argentina
11.3.1.4. Rest of Latin America
11.3.2. By Product Type
11.3.3. By End-use
11.4. Market Attractiveness Analysis
11.4.1. By Country
11.4.2. By Product Type
11.4.3. By End-use
11.5. Key Takeaways
12. Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034
12.1. Introduction
12.2. Historical Market Size (US$ million) and Volume Trend Analysis By Market Taxonomy, 2019 to 2023
12.3. Market Size (US$ million) and Volume Forecast By Market Taxonomy, 2024 to 2034
12.3.1. By Country
12.3.1.1. Germany
12.3.1.2. United Kingdom
12.3.1.3. France
12.3.1.4. Italy
12.3.1.5. Spain
12.3.1.6. BENELUX
12.3.1.7. Nordic
12.3.1.8. Russia
12.3.1.9. Poland
12.3.1.10. Rest of Europe
12.3.2. By Product Type
12.3.3. By End-use
12.4. Market Attractiveness Analysis
12.4.1. By Country
12.4.2. By Product Type
12.4.3. By End-use
12.5. Key Takeaways
13. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034
13.1. Introduction
13.2. Historical Market Size (US$ million) and Volume Trend Analysis By Market Taxonomy, 2019 to 2023
13.3. Market Size (US$ million) and Volume Forecast By Market Taxonomy, 2024 to 2034
13.3.1. By Country
13.3.1.1. China
13.3.1.2. Japan
13.3.1.3. South Korea
13.3.2. By Product Type
13.3.3. By End-use
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Product Type
13.4.3. By End-use
13.5. Key Takeaways
14. South Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034
14.1. Introduction
14.2. Historical Market Size (US$ million) and Volume Trend Analysis By Market Taxonomy, 2019 to 2023
14.3. Market Size (US$ million) and Volume Forecast By Market Taxonomy, 2024 to 2034
14.3.1. By Country
14.3.1.1. India
14.3.1.2. Thailand
14.3.1.3. Malaysia
14.3.1.4. Indonesia
14.3.1.5. Singapore
14.3.1.6. Vietnam
14.3.1.7. Philippines
14.3.1.8. Rest of South Asia
14.3.2. By Product Type
14.3.3. By End-use
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Product Type
14.4.3. By End-use
14.5. Key Takeaways
15. Oceania Market Analysis 2019 to 2023 and Forecast 2024 to 2034
15.1. Introduction
15.2. Historical Market Size (US$ million) and Volume Trend Analysis By Market Taxonomy, 2019 to 2023
15.3. Market Size (US$ million) and Volume Forecast By Market Taxonomy, 2024 to 2034
15.3.1. By Country
15.3.1.1. Australia
15.3.1.2. New Zealand
15.3.2. By Product Type
15.3.3. By End-use
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Product Type
15.4.3. By End-use
15.5. Key Takeaways
16. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034
16.1. Introduction
16.2. Historical Market Size (US$ million) and Volume Trend Analysis By Market Taxonomy, 2019 to 2023
16.3. Market Size (US$ million) and Volume Forecast By Market Taxonomy, 2024 to 2034
16.3.1. By Country
16.3.1.1. GCC Countries
16.3.1.2. Turkiye
16.3.1.3. Egypt
16.3.1.4. South Africa
16.3.1.5. Rest of Middle East and Africa
16.3.2. By Product Type
16.3.3. By End-use
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Product Type
16.4.3. By End-use
16.5. Key Takeaways
17. Country-level Market Analysis, 2022
17.1. United States Market Analysis
17.1.1. By Product Type
17.1.2. By End-use
17.2. Canada Market Analysis
17.2.1. By Product Type
17.2.2. By End-use
17.3. Brazil Market Analysis
17.3.1. By Product Type
17.3.2. By End-use
17.4. Mexico Market Analysis
17.4.1. By Product Type
17.4.2. By End-use
17.5. Argentina Market Analysis
17.5.1. By Product Type
17.5.2. By End-use
17.6. Germany Market Analysis
17.6.1. By Product Type
17.6.2. By End-use
17.7. United Kingdom Market Analysis
17.7.1. By Product Type
17.7.2. By End-use
17.8. France Market Analysis
17.8.1. By Product Type
17.8.2. By End-use
17.9. Italy Market Analysis
17.9.1. By Product Type
17.9.2. By End-use
17.10. Spain Market Analysis
17.10.1. By Product Type
17.10.2. By End-use
17.11. Belgium Market Analysis
17.11.1. By Product Type
17.11.2. By End-use
17.12. Netherlands Market Analysis
17.12.1. By Product Type
17.12.2. By End-use
17.13. Nordic Market Analysis
17.13.1. By Product Type
17.13.2. By End-use
17.14. Russia Market Analysis
17.14.1. By Product Type
17.14.2. By End-use
17.15. Poland Market Analysis
17.15.1. By Product Type
17.15.2. By End-use
17.16. China Market Analysis
17.16.1. By Product Type
17.16.2. By End-use
17.17. Japan Market Analysis
17.17.1. By Product Type
17.17.2. By End-use
17.18. South Korea Market Analysis
17.18.1. By Product Type
17.18.2. By End-use
17.19. India Market Analysis
17.19.1. By Product Type
17.19.2. By End-use
17.20. Thailand Market Analysis
17.20.1. By Product Type
17.20.2. By End-use
17.21. Malaysia Market Analysis
17.21.1. By Product Type
17.21.2. By End-use
17.22. Vietnam Market Analysis
17.22.1. By Product Type
17.22.2. By End-use
17.23. Philippines Market Analysis
17.23.1. By Product Type
17.23.2. By End-use
17.24. Indonesia Market Analysis
17.24.1. By Product Type
17.24.2. By End-use
17.25. Singapore Market Analysis
17.25.1. By Product Type
17.25.2. By End-use
17.26. Australia Market Analysis
17.26.1. By Product Type
17.26.2. By End-use
17.27. New Zealand Market Analysis
17.27.1. By Product Type
17.27.2. By End-use
17.28. GCC Countries Market Analysis
17.28.1. By Product Type
17.28.2. By End-use
17.29. Turkiye Market Analysis
17.29.1. By Product Type
17.29.2. By End-use
17.30. Egypt Market Analysis
17.30.1. By Product Type
17.30.2. By End-use
17.31. South Africa Market Analysis
17.31.1. By Product Type
17.31.2. By End-use
18. Market Structure Analysis
18.1. Global Competition - a Dashboard View
18.2. Industry Structure Analysis
18.2.1. % tier 1 market players
18.2.2. % tier 2 market players
18.2.3. % tier 3 market players
18.3. Global Market Company Share Analysis
18.3.1. For Tier 1 Market Players, 2024
18.3.2. Company Market Share Analysis of Top 5 Players, By Region
18.4. Key Participants Market Presence (Intensity Mapping) by Region
19. Competition Analysis
19.1. Competition Dashboard
19.2. Competition Benchmarking
19.3. Competition Deep Dive
19.3.1. Jennewein Biotechnologie GmbH
19.3.1.1. Product Portfolio
19.3.1.2. Product Claim
19.3.1.3. Revenue by Market Segments (Product/ channel/Region)
19.3.1.4. Sales Footprint
19.3.1.5. Strategy Overview
19.3.1.5.1. Marketing Strategy
19.3.1.5.2. Product Strategy
19.3.1.5.3. Channel Strategy
19.3.1.6. SWOT Analysis
19.3.2. KYOWA HAKKO BIO CO. LTD.
19.3.3. DSM
19.3.4. Nestle Health Science
19.3.5. DUPONT
19.3.6. zuChem Inc.
19.3.7. Glycosyn LLC
19.3.8. Elicityl SA
19.3.9. Dextra Laboratories Limited
19.3.10. Carbosynth Limited
19.3.11. Other Players (On Additional Requests)
20. Assumptions and Acronyms Used
21. Research Methodology
Explore Food and Beverage Insights
View Reports
Human Milk Oligosaccharide (HMO) Market
